BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry.

波士顿，2023年10月13日（GLOBE NEWSWIRE）-Covant Therapeutics，一家创新的共价药物发现公司，很高兴宣布任命Vincent Hennemand担任首席执行官（首席执行官）。Vincent Hennemand是一位经验丰富的高管，在制药和生物技术行业拥有杰出的职业生涯。

With an exceptional track record of leadership, a passion for advancing healthcare, novel classes of therapeutics, and in-depth experience in immunology therapies, Vincent is poised to guide Covant Therapeutics into a new era of growth, innovation, and patient-centric excellence. Vincent joins Covant Therapeutics from his previous role as COO at Intergalactic Therapeutics, where he played an instrumental role in driving growth from the inception of the company, overseeing all business operations, and enabling strategic partnerships.

凭借卓越的领导力记录，对推进医疗保健的热情，新型疗法以及对免疫疗法的深入经验，Vincent有望将Covant therapeutics引向成长，创新和以患者为中心的卓越新时代。Vincent加入了Covant Therapeutics，从他以前在Intergalactic Therapeutics担任首席运营官的角色开始，在推动公司成立，监督所有业务运营以及实现战略合作伙伴关系方面发挥了重要作用。

Prior to Intergalactic, he spent almost two decades in management consulting, large pharma and venture capital at Bain, Sanofi and Puretech Health. At Sanofi, he held various roles from manufacturing to program management in R&D immunology and became Chief of Staff of Dr. Elias Zerhouni, President Global R&D and former NIH Director.

在Intergalactic之前，他在贝恩，赛诺菲和Puretech Health的管理咨询，大型制药和风险投资方面花费了将近二十年的时间。在赛诺菲，他在研发免疫学领域担任从制造到项目管理的各种角色，并成为Elias Zerhouni博士，全球研发总裁和前NIH主任的职员。

He then later advanced into the corporate venture group at Sanofi-Genzyme. At Puretech, he served as SVP of corporate strategy and business development while leading the immuno-inflammation effort. Commenting on his appointment, Vincent Hennemand stated, 'I am deeply honored to lead Covant Therapeutics at this promising moment.

然后，他进入赛诺菲健赞公司的企业风险集团。在Puretech，他在领导免疫炎症工作的同时，担任公司战略和业务发展的SVP。Vincent Hennemand在评论他的任命时表示：“我非常荣幸在这个充满希望的时刻领导Covant Therapeutics。

The company's dedication to improving patient lives through groundbreaking covalent small molecules, particularly in immunology and inflammation, aligns seamlessly with my own values and aspirations. I am excited to work alongside the exceptional team at Covant as we .

该公司致力于通过开创性的共价小分子改善患者生活，特别是在免疫学和炎症方面，与我自己的价值观和愿望无缝结合。我很高兴像我们一样与Covant的卓越团队一起工作。